- Home
- GKOS vs NEA Comparison
GKOS vs NEA Comparison
Compare GKOS & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- NEA
- Stock Information
- Founded
- GKOS 1998
- NEA 2002
- Country
- GKOS United States
- NEA United States
- Employees
- GKOS 995
- NEA N/A
- Industry
- GKOS Medical/Dental Instruments
- NEA Finance/Investors Services
- Sector
- GKOS Health Care
- NEA Finance
- Exchange
- GKOS Nasdaq
- NEA Nasdaq
- Market Cap
- GKOS 5.1B
- NEA N/A
- IPO Year
- GKOS 2015
- NEA N/A
- Fundamental
- Price
- GKOS $90.26
- NEA $10.70
- Analyst Decision
- GKOS Strong Buy
- NEA
- Analyst Count
- GKOS 13
- NEA 0
- Target Price
- GKOS $155.00
- NEA N/A
- AVG Volume (30 Days)
- GKOS 1.0M
- NEA 803.4K
- Earning Date
- GKOS 04-30-2025
- NEA 01-01-0001
- Dividend Yield
- GKOS N/A
- NEA 4.23%
- EPS Growth
- GKOS N/A
- NEA N/A
- EPS
- GKOS N/A
- NEA N/A
- Revenue
- GKOS $383,481,000.00
- NEA N/A
- Revenue This Year
- GKOS $27.84
- NEA N/A
- Revenue Next Year
- GKOS $27.99
- NEA N/A
- P/E Ratio
- GKOS N/A
- NEA N/A
- Revenue Growth
- GKOS 21.85
- NEA N/A
- 52 Week Low
- GKOS $77.91
- NEA $9.20
- 52 Week High
- GKOS $163.71
- NEA $11.37
- Technical
- Relative Strength Index (RSI)
- GKOS 41.57
- NEA 39.11
- Support Level
- GKOS $86.16
- NEA $10.62
- Resistance Level
- GKOS $94.55
- NEA $10.76
- Average True Range (ATR)
- GKOS 6.54
- NEA 0.20
- MACD
- GKOS 1.11
- NEA -0.01
- Stochastic Oscillator
- GKOS 54.51
- NEA 55.56
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.